18 21 24 27 30 ion-free survival (mo		Age <75 years (n = 84) ≥75 years (n = 68) <80 years (n = 115) ≥80 years (n = 37)  1.0 0.9 0.8 0.6 0.5 0.6 0.5 0.7 0.7 0.0 0.3 0.2 0.1 0.0 0.3 6  Patients at risk  <75 years 84 69 48 ≥75 years 68 49 38	Progression	18 21 24 n-free surviv	edian, months (95% CI 8.3 (6.8, 11.0) 9.7 (6.3, 14.5) 8.5 (6.9, 11.0) 8.6 (5.5, 27.6)
18 21 24 27 30 ion-free survival (mo	8.5 (6.9, 11.0) 0 33 36 39 42 45 onths)	≥75 years (n = 68) <80 years (n = 115) ≥80 years (n = 37) 1.0 0.9 0.8 0.8 0.7 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	9 12 15 Progressio	on-free surviv	9.7 (6.3, 14.5) 8.5 (6.9, 11.0) 8.6 (5.5, 27.6) 8.6 (5.5, 27.6)
18 21 24 27 30 ion-free survival (mo	0 33 36 39 42 45 onths)	<80 years (n = 115) ≥80 years (n = 37)  1.0 0.9 0.9 0.8 0.8 0.7 0.9 0.9 0.6 0.5 0.6 0.5 0.7 0.0 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	9 12 15 Progressio	on-free surviv	8.5 (6.9, 11.0) 8.6 (5.5, 27.6) 1 27 30 33 36 39 4 val (months)
ion-free survival (mo	onths)	280 years (n = 37)  1.0 0.9 0.8 0.8 0.7 0.9 0.6 0.5 0.6 0.5 0.7 0.0 0.7 0.0 0.7 0.0 0.7 0.7 0.7 0.7	9 12 15 Progressio	on-free surviv	8.6 (5.5, 27.6) 1 27 30 33 36 39 4 val (months)
ion-free survival (mo	onths)	1.0 0.9 0.8 0.8 0.7 0.6 0.5 0.4 0.4 0.6 0.3 0.2 0.1 0.0 0.3 0.2 0.1 0.0 0.3 0.2 0.1 0.0 0.3 0.3 0.3 0.3 0.3 0.3 0.3	9 12 15 Progressio	on-free surviv	1 27 30 33 36 39 4 val (months)
ion-free survival (mo	onths)	0.9 0.8 0.7 0.6 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0.3 6	Progression	on-free surviv	val (months)
ion-free survival (mo	onths)	Patients at risk	Progression	on-free surviv	val (months)
16 11 8 6 4	1 1 1 0 0	-<75 years 84 69 48			5 1 1 1 1
		— ≥75 ýears 68 49 38 — <80 years 115 92 66 — ≥80 years 37 26 20	29 18 11 27 19 15 43 28 18 13 9 8	11 8 6 5 3 2 12 9 7 4 2 1	5 4 1 1 1 1 0 0 0 0 5 4 1 1 1 1 0 0 0 0
Events, n	Median, months (95% CI)	chemotherapy for	Ev	ents, n	Median, months (95% CI)
41	8.6 (6.8, 12.2)	Yes (n = 74)		50	9.5 (5.8, 13.8)
End Total	27 30 33 36 39 42	1.0			27 30 33 36 39 43 al (months)
		41 8.6 (6.8, 12.2)	Events, n Median, months (95% CI)  41	metastatic disease Yes (n = 74)  1.0  1.0  1.0  1.0  1.0  1.0  1.0  1.	Events, n Median, months (95% CI)  41

Figure S4. Progression-free survival by investigator assessment. CI, confidence interval.

Patients at risk:

Patients at risk:

— Treatment-naïve 69 53 39 24 16 13 11 7 5 4 2 0 0 0 0 0 Previously treated 83 65 47 32 21 13 5 4 3 2 2 1 1 1 1 0

- Yes 74 58 42 30 21 13 5 4 3 2 2 1 1 1 0